LN-145-S1
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for LN-145-S1, covering 2023-10-12 to 2025-11-21. Get the full timeline:
Most recent: Clinical Trial Update: LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas [Phase 2]